427 related articles for article (PubMed ID: 26031367)
1. Interim PET After Two ABVD Cycles in Early-Stage Hodgkin Lymphoma: Outcomes Following the Continuation of Chemotherapy Plus Radiotherapy.
Simontacchi G; Filippi AR; Ciammella P; Buglione M; Saieva C; Magrini SM; Livi L; Iotti C; Botto B; Vaggelli L; Re A; Merli F; Ricardi U
Int J Radiat Oncol Biol Phys; 2015 Aug; 92(5):1077-1083. PubMed ID: 26031367
[TBL] [Abstract][Full Text] [Related]
2. Post-ABVD/pre-radiotherapy (18)F-FDG-PET provides additional prognostic information for early-stage Hodgkin lymphoma: a retrospective analysis on 165 patients.
Ciammella P; Filippi AR; Simontacchi G; Buglione M; Botto B; Mangoni M; Iotti C; Merli F; Marcheselli L; Bisi G; Ricardi U; Versari A
Br J Radiol; 2016; 89(1061):20150983. PubMed ID: 27022777
[TBL] [Abstract][Full Text] [Related]
3. US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816.
Press OW; Li H; Schöder H; Straus DJ; Moskowitz CH; LeBlanc M; Rimsza LM; Bartlett NL; Evens AM; Mittra ES; LaCasce AS; Sweetenham JW; Barr PM; Fanale MA; Knopp MV; Noy A; Hsi ED; Cook JR; Lechowicz MJ; Gascoyne RD; Leonard JP; Kahl BS; Cheson BD; Fisher RI; Friedberg JW
J Clin Oncol; 2016 Jun; 34(17):2020-7. PubMed ID: 27069074
[TBL] [Abstract][Full Text] [Related]
4. Low-dose consolidation radiation therapy for early stage unfavorable Hodgkin lymphoma.
Torok JA; Wu Y; Prosnitz LR; Kim GJ; Beaven AW; Diehl LF; Kelsey CR
Int J Radiat Oncol Biol Phys; 2015 May; 92(1):54-9. PubMed ID: 25863754
[TBL] [Abstract][Full Text] [Related]
5. Modification of initial therapy in early and advanced Hodgkin lymphoma, based on interim PET/CT is beneficial: a prospective multicentre trial of 355 patients.
Dann EJ; Bairey O; Bar-Shalom R; Mashiach T; Barzilai E; Kornberg A; Akria L; Tadmor T; Filanovsky K; Abadi U; Kagna O; Ruchlemer R; Abdah-Bortnyak R; Goldschmidt N; Epelbaum R; Horowitz NA; Lavie D; Ben-Yehuda D; Shpilberg O; Paltiel O
Br J Haematol; 2017 Sep; 178(5):709-718. PubMed ID: 28589704
[TBL] [Abstract][Full Text] [Related]
6. Interim fluoro-2-deoxy-D-glucose-PET predicts response and progression-free survival in patients with Hodgkin lymphoma and HIV infection.
Okosun J; Warbey V; Shaw K; Montoto S; Fields P; Marcus R; Virchis A; McNamara C; Bower M; Cwynarski K
AIDS; 2012 Apr; 26(7):861-5. PubMed ID: 22333746
[TBL] [Abstract][Full Text] [Related]
7. In vivo treatment sensitivity testing with positron emission tomography/computed tomography after one cycle of chemotherapy for Hodgkin lymphoma.
Hutchings M; Kostakoglu L; Zaucha JM; Malkowski B; Biggi A; Danielewicz I; Loft A; Specht L; Lamonica D; Czuczman MS; Nanni C; Zinzani PL; Diehl L; Stern R; Coleman M
J Clin Oncol; 2014 Sep; 32(25):2705-11. PubMed ID: 25071108
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy Response Assessment by FDG-PET-CT in Early-stage Classical Hodgkin Lymphoma: Moving Beyond the Five-Point Deauville Score.
Milgrom SA; Dong W; Akhtari M; Smith GL; Pinnix CC; Mawlawi O; Rohren E; Garg N; Chuang H; Yehia ZA; Reddy JP; Gunther JR; Khoury JD; Suki T; Osborne EM; Oki Y; Fanale M; Dabaja BS
Int J Radiat Oncol Biol Phys; 2017 Feb; 97(2):333-338. PubMed ID: 28068241
[TBL] [Abstract][Full Text] [Related]
9. Combined modality treatment for PET-positive non-Hodgkin lymphoma: favorable outcomes of combined modality treatment for patients with non-Hodgkin lymphoma and positive interim or postchemotherapy FDG-PET.
Halasz LM; Jacene HA; Catalano PJ; Van den Abbeele AD; Lacasce A; Mauch PM; Ng AK
Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):e647-54. PubMed ID: 22607911
[TBL] [Abstract][Full Text] [Related]
10. Prognostic factors for advanced-stage human immunodeficiency virus-associated classical Hodgkin lymphoma treated with doxorubicin, bleomycin, vinblastine, and dacarbazine plus combined antiretroviral therapy: a multi-institutional retrospective study.
Castillo JJ; Bower M; Brühlmann J; Novak U; Furrer H; Tanaka PY; Besson C; Montoto S; Cwynarski K; Abramson JS; Dalia S; Bibas M; Connors JM; Furman M; Nguyen ML; Cooley TP; Beltran BE; Collins JA; Vose JM; Xicoy B; Ribera JM;
Cancer; 2015 Feb; 121(3):423-31. PubMed ID: 25251326
[TBL] [Abstract][Full Text] [Related]
11. Hodgkin lymphoma: an Australian experience of ABVD chemotherapy in the modern era.
Jalali A; Ha FJ; Chong G; Grigg A; Mckendrick J; Schwarer AP; Doig R; Hamid A; Hawkes EA
Ann Hematol; 2016 Apr; 95(5):809-16. PubMed ID: 26878861
[TBL] [Abstract][Full Text] [Related]
12. High-Risk, Advanced-Stage Hodgkin Lymphoma: The Impact of Combined Escalated BEACOPP and ABVD Treatment in Patients Who Rapidly Achieve Metabolic Complete Remission on Interim FDG-PET/CT Scan.
Kedmi M; Apel A; Davidson T; Levi I; Dann EJ; Polliack A; Ben-Bassat I; Nagler A; Avigdor A
Acta Haematol; 2016; 135(3):156-61. PubMed ID: 26588173
[TBL] [Abstract][Full Text] [Related]
13. 18F-FDG PET after 2 cycles of ABVD predicts event-free survival in early and advanced Hodgkin lymphoma.
Cerci JJ; Pracchia LF; Linardi CC; Pitella FA; Delbeke D; Izaki M; Trindade E; Soares J; Buccheri V; Meneghetti JC
J Nucl Med; 2010 Sep; 51(9):1337-43. PubMed ID: 20720036
[TBL] [Abstract][Full Text] [Related]
14. Optimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second malignant neoplasms, overall and progression-free survival: individual participant data analysis.
Franklin J; Eichenauer DA; Becker I; Monsef I; Engert A
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD008814. PubMed ID: 28901021
[TBL] [Abstract][Full Text] [Related]
15. Involved-site image-guided intensity modulated versus 3D conformal radiation therapy in early stage supradiaphragmatic Hodgkin lymphoma.
Filippi AR; Ciammella P; Piva C; Ragona R; Botto B; Gavarotti P; Merli F; Vitolo U; Iotti C; Ricardi U
Int J Radiat Oncol Biol Phys; 2014 Jun; 89(2):370-5. PubMed ID: 24613810
[TBL] [Abstract][Full Text] [Related]
16. Early Positron Emission Tomography Response-Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 Trial.
André MPE; Girinsky T; Federico M; Reman O; Fortpied C; Gotti M; Casasnovas O; Brice P; van der Maazen R; Re A; Edeline V; Fermé C; van Imhoff G; Merli F; Bouabdallah R; Sebban C; Specht L; Stamatoullas A; Delarue R; Fiaccadori V; Bellei M; Raveloarivahy T; Versari A; Hutchings M; Meignan M; Raemaekers J
J Clin Oncol; 2017 Jun; 35(16):1786-1794. PubMed ID: 28291393
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of mid- and post-ABVD PET imaging in Hodgkin's lymphoma: the importance of involved-field radiotherapy.
Sher DJ; Mauch PM; Van Den Abbeele A; LaCasce AS; Czerminski J; Ng AK
Ann Oncol; 2009 Nov; 20(11):1848-53. PubMed ID: 19541793
[TBL] [Abstract][Full Text] [Related]
18. Response-guided ABVD chemotherapy plus involved-field radiation therapy for intermediate-stage Hodgkin lymphoma in the pre-positron emission tomography era: a Gruppo Italiano Studio Linfomi (GISL) prospective trial.
Iannitto E; Minardi V; Gobbi PG; Calvaruso G; Tripodo C; Marcheselli L; Luminari S; Merli F; Baldini L; Stelitano C; Callea V; Petrini M; Angrilli F; Quarta G; Vallisa D; Molica S; Liardo E; Polimeno G; Brugiatelli M; Federico M
Clin Lymphoma Myeloma; 2009 Apr; 9(2):138-44. PubMed ID: 19406724
[TBL] [Abstract][Full Text] [Related]
19. Very low utility of surveillance imaging in early-stage classic Hodgkin lymphoma treated with a combination of doxorubicin, bleomycin, vinblastine, and dacarbazine and radiation therapy.
Gandikota N; Hartridge-Lambert S; Migliacci JC; Yahalom J; Portlock CS; Schöder H
Cancer; 2015 Jun; 121(12):1985-92. PubMed ID: 25739719
[TBL] [Abstract][Full Text] [Related]
20. Risk-adapted therapy with three or six cycles of doxorubicin/bleomycin/vinblastine/dacarbazine plus involved-field radiation therapy in Hodgkin lymphoma, based on prognosis at diagnosis and early response: results from the GATLA study.
Pavlovsky S; Corrado C; Pavlovsky MA; Prates MV; Zoppegno L; Giunta M; Cerutti I; Palomino E; Pagani F; Lastiri F; Bar D; Bezares RF; Avila G
Clin Lymphoma Myeloma Leuk; 2010 Jun; 10(3):181-5. PubMed ID: 20511162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
